TimesSquare Capital Management LLC Invests $7.53 Million in Charles River Laboratories International, Inc. (NYSE:CRL)

TimesSquare Capital Management LLC acquired a new position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 31,835 shares of the medical research company's stock, valued at approximately $7,526,000. TimesSquare Capital Management LLC owned 0.06% of Charles River Laboratories International as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently modified their holdings of CRL. abrdn plc increased its stake in shares of Charles River Laboratories International by 872.0% in the 4th quarter. abrdn plc now owns 121,807 shares of the medical research company's stock worth $28,795,000 after acquiring an additional 109,275 shares in the last quarter. Regency Capital Management Inc. DE bought a new position in Charles River Laboratories International in the fourth quarter valued at about $3,703,000. WCM Investment Management LLC bought a new position in shares of Charles River Laboratories International in the 4th quarter worth approximately $1,396,000. DekaBank Deutsche Girozentrale boosted its stake in shares of Charles River Laboratories International by 98.6% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 14,094 shares of the medical research company's stock worth $3,333,000 after acquiring an additional 6,997 shares during the last quarter. Finally, AMG National Trust Bank bought a new stake in Charles River Laboratories International during the third quarter valued at about $1,119,000. Institutional investors own 98.91% of the company's stock.

Wall Street Analyst Weigh In

CRL has been the subject of a number of analyst reports. TheStreet upgraded Charles River Laboratories International from a "c+" rating to a "b-" rating in a research note on Friday, March 1st. Argus boosted their price target on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the stock a "buy" rating in a research note on Monday, March 18th. Guggenheim lowered Charles River Laboratories International from a "buy" rating to a "neutral" rating in a research report on Thursday, February 15th. Citigroup boosted their target price on Charles River Laboratories International from $215.00 to $250.00 and gave the stock a "neutral" rating in a research report on Thursday, February 15th. Finally, Evercore ISI lifted their price objective on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an "outperform" rating in a research note on Thursday, February 15th. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Charles River Laboratories International has an average rating of "Moderate Buy" and a consensus target price of $253.38.

Charles River Laboratories International Trading Down 0.9 %

CRL stock traded down $2.17 during midday trading on Friday, reaching $227.92. The company's stock had a trading volume of 842,499 shares, compared to its average volume of 552,220. The firm has a market capitalization of $11.74 billion, a price-to-earnings ratio of 24.98, a PEG ratio of 1.83 and a beta of 1.44. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52. The stock has a fifty day simple moving average of $250.70 and a two-hundred day simple moving average of $225.27.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, beating analysts' consensus estimates of $2.05 by $0.22. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $997.24 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

Insider Buying and Selling

In related news, EVP Shannon M. Parisotto sold 5,882 shares of the company's stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares of the company's stock, valued at $626,155.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, EVP Shannon M. Parisotto sold 5,882 shares of the firm's stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the sale, the executive vice president now owns 2,596 shares of the company's stock, valued at $626,155.20. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP William D. Barbo sold 4,050 shares of the business's stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the transaction, the vice president now owns 22,879 shares of the company's stock, valued at $5,685,431.50. The disclosure for this sale can be found here. Insiders have sold a total of 14,932 shares of company stock valued at $3,693,663 over the last quarter. 1.30% of the stock is owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).